Home / Health / Cortisol Pill Offers Hope for Alzheimer's

Cortisol Pill Offers Hope for Alzheimer's

Summary

  • A daily pill may slow Alzheimer's progression by 30% in older patients.
  • The drug targets cortisol levels in specific brain areas linked to the disease.
  • Early trials show promise for those over 75 years old.
Cortisol Pill Offers Hope for Alzheimer's

A daily oral medication targeting cortisol in the brain is demonstrating potential to slow the progression of Alzheimer's disease, particularly in individuals over the age of 75. Early trial results indicate a 30% reduction in disease progression for this age group.

The drug, known as emestedastat or Xanamem, functions by blocking cortisol production in key brain regions associated with Alzheimer's. While the overall trial did not show statistically significant benefits across all participants, the specific results for older individuals are considered promising and comparable to newer monoclonal antibody treatments.

This development is significant as it offers a potential treatment for more advanced Alzheimer's cases, often affecting older patients. Researchers suggest the drug may also reduce brain inflammation, a common marker in older individuals with the disease. The pill is expected to be less costly and have fewer side effects than current therapies.

Recent advancements in Alzheimer's research also include experimental mRNA nose drops developed by University of Sydney researchers, which have shown success in boosting cognition and preventing memory loss in mice. These developments signal a dynamic period for Alzheimer's treatment following decades of limited progress. The next phase of Xanamem trials is anticipated to involve 700 patients, with a potential market release targeted for 2030.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571